^
Association details:
| Biomarker: | MYCN amplification + ALK rearrangement |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Excerpt:
...brigatinib and crizotinib both inhibited cell growth of ALK addicted neuroblastoma lines...CLB-GE the IC50 values for...crizotinib...225 ± 26…
DOI:
10.18632/oncotarget.8508
